Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial (Q33423800)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial |
scientific article |
Statements
1 reference
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial (English)
1 reference
Andrew X Zhu
1 reference
Joon Oh Park
1 reference
Baek-Yeol Ryoo
1 reference
Chia-Jui Yen
1 reference
Ronnie Poon
1 reference
Davide Pastorelli
1 reference
Jean-Frederic Blanc
1 reference
Ari D Baron
1 reference
Tulio Eduardo Flesch Pfiffer
1 reference
Takuji Okusaka
1 reference
Katerina Kubackova
1 reference
Jorg Trojan
1 reference
Javier Sastre
1 reference
Shao-Chun Chang
1 reference
Paolo B Abada
1 reference
Ling Yang
1 reference
Jonathan D Schwartz
1 reference
REACH Trial Investigators
1 reference
1 reference
Identifiers
1 reference